1. The druggability of intracellular nucleotide-degrading enzymes

   • Chiara Rampazzo
   • Maria Grazia Tozzi
   • Lars Petter Jordheim

   Review Article 27 November 2015 Pages: 883 - 893

   

2. The selective estrogen receptor modulators in breast cancer prevention

   • Fangxuan Li
   • Jinli Dou
   • Juntian Liu

   Review Article 20 January 2016 Pages: 895 - 903

3. Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes

   • Jingya Zhang
   • Linna Zhang
   • Guisen Zhao

   Review Article 18 January 2016 Pages: 905 - 926

   

4. Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data

   • Thierry Wendling
   • Hitesh Mistry
   • Leon Aarons

   Original Article Open access 03 March 2016 Pages: 927 - 938

   

5. Bleomycin pharmacokinetics of bolus bleomycin dose in elderly cancer patients treated with electrochemotherapy

   • Ales Groselj
   • Mojca Krzan
   • Maja Cemazar

   Original Article 18 March 2016 Pages: 939 - 947

   

6. A phase II, open-label trial of bortezomib (VELCADE^®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer

   • E. Kontopodis
   • A. Kotsakis
   • S. Agelaki

   Original Article 19 March 2016 Pages: 949 - 956

   

7. A phase II prospective study of the trastuzumab combined with 5-weekly S-1 and CDDP therapy for HER2-positive advanced gastric cancer

   • Hiromi Kataoka
   • Yoshinori Mori
   • Takashi Joh

   Original Article 22 March 2016 Pages: 957 - 962

   

8. Inhibition of Glut1 by WZB117 sensitizes radioresistant breast cancer cells to irradiation

   • Fei Zhao
   • Jia Ming
   • Linjun Fan

   Original Article 24 March 2016 Pages: 963 - 972

   

9. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers

   • Muhammad R. Khawaja
   • Alpa M. Nick
   • Aung Naing

   Original Article 24 March 2016 Pages: 973 - 977

   

10. Role of adjuvant therapy after R0 resection for patients with distal cholangiocarcinoma

    • Young Saing Kim
    • In Gyu Hwang
    • Joon Oh Park

    Original Article 26 March 2016 Pages: 979 - 985

    

11. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors

    • Satoshi Yoshiba
    • Mendel Jansen
    • Jeanne Mendell

    Original Article 26 March 2016 Pages: 987 - 996

    

12. A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors

    • Toshio Shimizu
    • Kazuya Fukuoka
    • Kazuhiko Nakagawa

    Original Article Open access 30 March 2016 Pages: 997 - 1003

    

13. Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience

    • Kenichiro Kudo
    • Katsuyuki Hotta
    • Katsuyuki Kiura

    Original Article 31 March 2016 Pages: 1005 - 1009

14. Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer

    • Masato Karayama
    • Naoki Inui
    • Takafumi Suda

    Original Article 31 March 2016 Pages: 1011 - 1018

    

15. Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor

    • Masahito Ogasawara
    • Yutaka Nakamura
    • Yutaka Takaoka

    Original Article 04 April 2016 Pages: 1019 - 1029

    

16. Distinctive impact of pre-existing interstitial lung disease on the risk of chemotherapy-related lung injury in patients with lung cancer

    • Yuichi Ozawa
    • Daisuke Akahori
    • Takafumi Suda

    Original Article 05 April 2016 Pages: 1031 - 1038

17. Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice

    • Andrea N. Edginton
    • Eric I. Zimmerman
    • John C. Panetta

    Original Article 06 April 2016 Pages: 1039 - 1052

    

18. Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy

    • Neta Goldschmidt
    • Geffen Kleinstern
    • Moshe E Gatt

    Original Article 07 April 2016 Pages: 1053 - 1060

    

19. Silence of long noncoding RNA UCA1 inhibits malignant proliferation and chemotherapy resistance to adriamycin in gastric cancer

    • Chao Shang
    • Yan Guo
    • Baojun Huang

    Original Article 07 April 2016 Pages: 1061 - 1067

    

20. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer

    • Fadi Farhat
    • Joseph G. Kattan
    • Marwan Ghosn

    Original Article 08 April 2016 Pages: 1069 - 1077

    

21. A phase I dose escalation study of NK012, an SN-38 incorporating macromolecular polymeric micelle

    • Howard A. Burris
    • Jeffrey R. Infante
    • Suzanne F. Jones

    Original Article 09 April 2016 Pages: 1079 - 1086

    

22. The anti-angiogenic effect of dexamethasone in a murine hepatocellular carcinoma model by augmentation of gluconeogenesis pathway in malignant cells

    • Fei Shang
    • Mingming Liu
    • Ruijuan Xiu

    Original Article 12 April 2016 Pages: 1087 - 1096

    

23. Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer

    • Rabih Said
    • Eugenia Kakadiaris
    • Apostolia M. Tsimberidou

    Original Article 16 April 2016 Pages: 1097 - 1102